Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis [Corrigendum]

Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis [Corrigendum]

Nandlal L, Perumal R, Naidoo K. Infect Drug Resist. 2022;15:4971-4984. Table 2 Performance of WHO-Endorsed Molecular Diagnostics for Drug-Resistant TB Diagnosis and Drug-Susceptibility Testing The authors have advised that there is an error in Table 2 on pages 4975 and 4976. The text "$1240&quo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infection and drug resistance 2022-10, Vol.15, p.6081-6084
Hauptverfasser: Nandlal, Louansha, Perumal, Rubeshan, Naidoo, Kogieleum
Format: Artikel
Sprache:eng
Schlagworte:
Corrigendum
diagnosis
Drug resistance
molecular assays
point of care
tuberculosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nandlal L, Perumal R, Naidoo K. Infect Drug Resist. 2022;15:4971-4984. Table 2 Performance of WHO-Endorsed Molecular Diagnostics for Drug-Resistant TB Diagnosis and Drug-Susceptibility Testing The authors have advised that there is an error in Table 2 on pages 4975 and 4976. The text "$1240" in the Cost Per Test column for the TRUENAT MTB-RIF Dx (Molbio) 2020 row should read "$12.40". This error was introduced by the Editorial staff during the publication process. The correct Table 2 is shown below.
ISSN:1178-6973
1178-6973
DOI:10.2147/IDR.S390405